Trial Profile
An Open-Label, Relative Bioavailability Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ropinirole Implants in Patients With Parkinson's Disease Switched From Oral Immediate-Release Ropinirole While on L-Dopa
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 09 May 2023
Price :
$35
*
At a glance
- Drugs Ropinirole (Primary) ; Ropinirole (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Pharmacokinetics; Proof of concept; Therapeutic Use
- Sponsors Titan Pharmaceuticals
- 04 Feb 2020 Status changed from suspended to discontinued.
- 19 Apr 2019 Planned End Date changed from 1 Dec 2018 to 1 Jul 2020.
- 19 Apr 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jul 2020.